Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis

Abstract

Abstract Background： In the recent outbreak of novel coronavirus infection worldwide, the risk of thrombosis and bleeding should be concerned. Objectives: We aimed to observe the dynamic changes of D-dimer levels during disease progression to evaluate their value for thrombosis. Methods: In this study, we report the clinical and laboratory results of 57 patients with confirmed COVID-19 pneumonia and 46 patients with confirmed community-acquired bacterial pneumonia (CAP). And their concentrations of D-dimer, infection-related biomarkers, and conventional coagulation were retrospectively analyzed. Results: On admission, both in COVID-19 patients and CAP patients, D-dimer levels were significantly increased, and compared with CAP patients, D-Dimer levels were higher in COVID-19 patients (P<0.05). Besides, we found that in COVID-19 patients, D-dimer were related with markers of inflammation, especially with hsCRP (R=0.426, P<0.05), and after treatments, D-dimer levels decreased which was synchronous with hsCRP levels in patients with good clinical prognosis, but there were still some patients with anomalous increasing D-dimer levels after therapy. Conclusions: Elevated baseline D-dimer levels are associated with inflammation in COVID-19 patients, and the abnormal changes of D-dimer and inflammatory factors suggest that anticoagulant therapy might be needed.